U.S. policy & evidence
A working collection of primary documents, research records, and public tools for following ibogaine’s changing U.S. landscape state by state.
This page is designed for careful source-checking: it distinguishes official records and peer-reviewed evidence from claims that cannot establish legal status, safety, or clinical effect.
How to use this hub
A state-by-state landscape is only as reliable as the source behind it.
Legislation may be introduced, amended, enacted, vetoed, or left pending; agency rules and public funding decisions follow separate processes. Start with the broader U.S. ibogaine policy landscape, then compare the cited document’s date, jurisdiction, and legal effect before drawing conclusions.
For orientation to the project’s sourcing approach and limits, the principles behind this independent resource explain why primary materials are given priority. The entries below are curated for journalists, researchers, and policymakers, not as treatment guidance or provider recommendations.
Primary repositories
Use these records to establish what has been registered, what a federal agency says, and where a rulemaking action stands. A database entry or agency statement should not be treated as proof that a therapy is approved or available.
This U.S. National Library of Medicine registry is the primary public index for registered studies and includes key protocol fields, sponsor information, recruitment status, and record history.
Last checked: October 6, 2026FDA’s official materials provide the most direct federal context for drug oversight and safety communications, including the distinction between investigational research and market approval.
Last checked: October 6, 2026The DEA’s current controlled-substances schedule is a federal reference point for checking how ibogaine is classified under the Controlled Substances Act.
Last checked: October 6, 2026Regulations.gov is the official cross-agency docket portal for locating proposed rules, supporting materials, and public comments when a federal rulemaking record exists.
Last checked: October 6, 2026Evidence trail
Searchable abstracts are useful starting points, but methods, adverse events, study size, follow-up, and conflicts of interest require reading the complete publication whenever possible. PubMed’s ibogaine results are maintained by the National Library of Medicine and offer a durable route to indexed biomedical literature.
For basic terminology, the overview of ibogaine’s history and chemistry can help identify commonly used names, but it is not a substitute for the underlying study or official legal text. The systematic review of ibogaine treatment studies is a useful example of why research findings should be read alongside stated limitations and safety concerns.
Questions about possible benefits should remain separate from questions about legal status or clinical suitability. The material at ibogaine therapy benefits illustrates why health-related claims should be checked against original research rather than repeated as settled conclusions.
Notable jurisdictions
Legislative trackers help locate proposals, but an enrolled bill, session law, agency notice, or official program page is needed to determine what was actually adopted and what remains under consideration.
The Texas Legislature Online portal is the official place to check bill text, actions, authors, and legislative history for proposals involving research or policy activity.
Last checked: October 6, 2026The Kentucky Legislative Record provides official bill and session materials, making it the appropriate starting point for confirming the status of Kentucky proposals.
Last checked: October 6, 2026The Colorado General Assembly bill search supplies official bill texts, votes, amendments, and actions needed to distinguish a proposal from enacted law.
Last checked: October 6, 2026“A proposal, a study registration, and an enacted policy are different kinds of evidence. Each should be named for what it is.”
Research practice
These routes can help clarify how research is governed, where patent claims are published, and how to request records without assuming access or outcomes.
The HHS human-subject protections regulations are an authoritative federal framework for research involving human participants; individual study oversight may also depend on the reviewing institution and protocol.
Last checked: October 6, 2026Google Patents offers searchable patent documents and cited records, while the USPTO remains the official federal patent authority; search results identify filings and claims, not proof of clinical validity or legal availability.
Last checked: October 6, 2026FOIA.gov explains the federal Freedom of Information Act process and directs requesters to agency FOIA offices; state public-records requests should go to the relevant state agency or legislative custodian under that jurisdiction’s law.
Last checked: October 6, 2026Commercial treatment listings are not included here and do not establish a legal or evidence-based endorsement. For context about options discussed outside the United States, material on ibogaine treatment centers in Mexico should be evaluated independently against applicable law, safety evidence, and original documentation.
Last checked: October 6, 2026Keep the record clear
Claims about addiction, Alzheimer’s disease, or dementia require especially careful separation from policy records and clinical evidence. Compare statements at ibogaine for addiction treatment, ibogaine and Alzheimer’s, ibogaine and dementia, and ibogaine alternatives with primary sources before treating any claim as established.